Peptide Vaccine Strategies in the Treatment of Cancer
- *Corresponding Author:
- George E Peoples, MD FACS
Department of Surgery, General Surgery Service
Brooke Army Medical Center, 3851 Roger Brooke Drive
Ft. Sam Houston, TX, 78234, USA
Tel: (210) 916-1117
Fax: (210) 916-6658
E-mail: [email protected]
Received Date: November 03, 2012; Accepted Date: April 23, 2013; Published Date: April 25, 2013
Citation: Vreeland TJ, Hale DK, Clifton GT, Sears AK, Mittendorf EA, et al. (2013) Peptide Vaccine Strategies in the Treatment of Cancer. J Proteomics Bioinform 6:081-084.doi:10.4172/jpb.1000265
Copyright: © 2013 Vreeland TJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The goal of vaccine researchers has been induction of a specific and active immune response, which offers patients cancer therapy with limited toxicity and long-standing protection. There have been great strides made toward this goal, as evidenced by the recent FDA approval of Sipuleucel-T (Provenge). The simplest, most efficacious and most affordable vaccine strategy, however, remains an area of great debate. Multiple strategies exist, varying by number and type of target, as well as delivery method. The following review will summarize the most promising strategies for application of the cancer vaccine strategy, focusing on the bright future of peptide-based vaccines.